Identification of a synthetic peptide inducing cross-reactive antibodies binding to Rhipicephalus (Boophilus) decoloratus, Rhipicephalus (Boophilus) microplus, Hyalomma anatolicum anatolicum and Rhipicephalus appendiculatus BM86 homologues

Vaccine. 2009 Dec 10;28(1):261-9. doi: 10.1016/j.vaccine.2009.09.085. Epub 2009 Oct 4.


The BM86 antigen, originally identified in Rhipicephalus (Boophilus) microplus, is the basis of the only commercialized anti-tick vaccine. The long-term goal of our study is to improve BM86 based vaccines by induction of high levels of tick gut binding antibodies that are also cross-reactive with a range of BM86 homologues expressed in other important tick species. Here we have used a BD86 derived synthetic peptide, BD86-3, to raise a series of mouse monoclonal antibodies. One of these mAbs, named 12.1, recognized BM86 homologues in immuno-histochemical analyses in four out of five tick species including R. (B.) microplus, Rhipicephalus (Boophilus) decoloratus, Hyalomma anatolicum anatolicum and Rhipicephalus appendiculatus. Our results indicate that broadly cross-reactive tick gut binding antibodies can be induced after immunization with a synthetic peptide derived from the protein BD86.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antibodies, Monoclonal / immunology*
  • Cattle
  • Cross Reactions
  • Female
  • Humans
  • Hybridomas
  • Membrane Glycoproteins / immunology*
  • Mice
  • Mice, Inbred BALB C
  • Molecular Sequence Data
  • Peptides / immunology*
  • Recombinant Proteins / immunology*
  • Rhipicephalus / immunology
  • Sequence Alignment
  • Tick Infestations / immunology
  • Tick Infestations / prevention & control*
  • Vaccines / immunology*
  • Vaccines, Subunit / immunology
  • Vaccines, Virosome / immunology


  • Antibodies, Monoclonal
  • BM86 protein, Boophilus
  • Membrane Glycoproteins
  • Peptides
  • Recombinant Proteins
  • Vaccines
  • Vaccines, Subunit
  • Vaccines, Virosome